Here's what to expect this week on Diagnostic Imaging.
In this week’s preview, here are some highlights of what you can expect to see coming soon on Diagnostic Imaging:
As the holidays and New Year approach, there is more end-of-year coverage to come. This week, look for a review of the most important things in ultrasound this year. Diagnostic Imaging spoke with Frost & Sullivan analysts Srikanth Kompalli and Suresh Kuppuswamy about the most significant developments during the year.
For additional end-of-year coverage, click here.
For more coverage based on industry expert insights and research, subscribe to the Diagnostic Imaging e-Newsletter here.
Insights from this year’s RSNA are still coming despite the meeting’s end roughly two weeks ago. This week, look for a video interview with Diane Strollo, M.D., visiting associate professor of cardiothoracic surgery at the University of Pittsburgh, about the importance of non-interpretive skills in the daily practice of radiology. She shared not only the benefit of these skills, but the dangers that exist if providers do not invest in them.
For more RSNA coverage, click here.
As COVID-19 cases continue to surge both nationwide and globally, there is new information out about the recurring patterns of disease and atypical neuroimaging manifestations of the virus in children who are infected. Look for coverage this week from an international study.
For additional COVID-19 coverage, click here.
Leading Breast Radiologists Discuss the USPSTF Breast Cancer Screening Recommendations
May 17th 2024In recognition of National Women’s Health Week, Dana Bonaminio, MD, Amy Patel, MD, and Stacy Smith-Foley, MD, shared their thoughts and perspectives on the recently updated breast cancer screening recommendations from the United States Preventive Services Task Force (USPSTF).
Appealing Prior Authorization Denials: Can it be Effective for Emerging Technologies?
May 14th 2024While radiologists and other providers may be discouraged by insurer denials saying the use of a technological advance is “unproven and investigational,” 82 percent of appeals for prior authorization denials were approved in 2021.